PMID- 25322333
OWN - NLM
STAT- MEDLINE
DCOM- 20150629
LR  - 20200914
IS  - 1521-0499 (Electronic)
IS  - 0190-2148 (Linking)
VI  - 40
IP  - 9
DP  - 2014 Nov
TI  - Chitosan aerosol inhalation alleviates lipopolysaccharide- induced pulmonary 
      fibrosis in rats.
PG  - 467-73
LID - 10.3109/01902148.2014.948231 [doi]
AB  - PURPOSE: Pulmonary fibrosis (PF) is an insidiously progressive scarring disorder 
      of the alveoli and is associated with high mortality. Currently, therapies 
      available are associated with restricted efficacy and side effects. This study 
      aimed to investigate the effect of chitosan aerosol inhalation on 
      lipopolysaccharide (LPS)-induced pulmonary remodeling and fibrosis in rats. 
      METHODS: A rat model of PF was established by intratracheal injection of LPS (5 
      mg/kg). Chitosan was nebulized to rats from day 4 to 28 after LPS injection. We 
      analyzed the effect of chitosan on LPS-induced pulmonary remodeling and fibrosis 
      by hematoxylin-eosin staining (HE), Masson staining, and the determination of the 
      hydroxyproline content. The expression intensities of matrix metalloproteinase-3 
      (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were analyzed by 
      western blots. RESULTS: Histological assessments showed that chitosan aerosol 
      inhalation attenuated the fibrotic changes in LPS-induced PF in rats. Compared 
      with the LPS group, the fibrosis parameters were significantly improved in the 
      LPS + chitosan group (LCh group), although not as good as those of the control 
      group. The expressions of MMP-3 and TIMP-1 in the LCh group were markedly less 
      than that of the LPS group on the 28th day. CONCLUSIONS: Our findings show that 
      chitosan aerosol inhalation inhibits the expression of MMP-3 and TIMP-1, and 
      ameliorates LPS-induced pulmonary remodeling and fibrosis in rats.
FAU - Zhou, Lu-Lu
AU  - Zhou LL
AD  - Department of Anesthesiology, Changzheng Hospital, Second Military Medical 
      University, Shanghai, People's Republic of China.
FAU - He, Xing-Ying
AU  - He XY
FAU - Xu, Feng-Ying
AU  - Xu FY
FAU - Du, Bo-Xiang
AU  - Du BX
FAU - Zou, Zui
AU  - Zou Z
FAU - Shi, Xue-Yin
AU  - Shi XY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Exp Lung Res
JT  - Experimental lung research
JID - 8004944
RN  - 0 (Lipopolysaccharides)
RN  - 0 (TIMP1 protein, rat)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 9007-34-5 (Collagen)
RN  - 9012-76-4 (Chitosan)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Administration, Inhalation
MH  - Animals
MH  - Chitosan/*administration & dosage
MH  - Collagen/metabolism
MH  - Lipopolysaccharides
MH  - Lung/metabolism/pathology
MH  - Male
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Pulmonary Fibrosis/metabolism/pathology/*prevention & control
MH  - Random Allocation
MH  - Rats, Sprague-Dawley
MH  - Tissue Inhibitor of Metalloproteinase-1/metabolism
OTO - NOTNLM
OT  - chitosan
OT  - lipopolysaccharide
OT  - matrix metallopmteinase-3
OT  - pulmonary fibrosis
OT  - tissue inhibitor of metalloproteinase-1
EDAT- 2014/10/17 06:00
MHDA- 2015/06/30 06:00
CRDT- 2014/10/17 06:00
PHST- 2014/10/17 06:00 [entrez]
PHST- 2014/10/17 06:00 [pubmed]
PHST- 2015/06/30 06:00 [medline]
AID - 10.3109/01902148.2014.948231 [doi]
PST - ppublish
SO  - Exp Lung Res. 2014 Nov;40(9):467-73. doi: 10.3109/01902148.2014.948231.